abs271.txt	the	aim	of	this	study	was	to	develop	a	new	drug	substance	with	low	toxicity	andeffective	inhibitory	activity	against	cisplatin-resistant	oral	cancer		thenaturally	produced	pterostilbene	was	selected	as	the	lead	compound	for	design	andsynthesis	of	a	series	of	bis(hydroxymethyl)propionate-based	prodrugs		allderivatives	were	screened	for	antiproliferative	effects	against	thecisplatin-resistant	oral	squamous	(car)	cell	line	and	the	results	indicated	thatseveral	compounds	demonstrated	superior	inhibitory	activity	compared	withpterostilbene	and	resveratrol		among	them		the	most	promising	compound		12		wasevaluated	for	in	vivo	antitumor	activity	in	a	car	xenograft	nude	mouse	model	obvious	antitumor	activity	was	observed	at	the	lowest	oral	dose	(25	mg/kg/day)	increasing	the	dose	of	12	to	100	mg/kg/day	reduced	the	tumor	size	to	22%	of	thecontrol	group		based	on	these	findings	as	well	as	the	extremely	low	toxicity	seenin	the	in	vivo	studies		we	believe	that	compound	12	could	serve	as	a	new	lead	forfurther	development	
